Facile Therapeutics
Sahil Khanna is on the Board of Advisors at Facile Therapeutics.
This person is not in the org chart
This person is not in any offices
Facile Therapeutics
Facile Therapeutics is bringing Ebselen into the clinic to demonstrate it will be effective in preventing the recurrence of CDI in a Proof-of-Concept (PoC) clinical trial.